The Costs and Benefits of Different Covid-19 Interventions
During 2020-21, the United States used a multifaceted approach to control SARS-CoV-2 (Covid-19) and reduce mortality and morbidity. This included non-medical interventions (NMIs), aggressive vaccine development and deployment, and research into more effective approaches to medically treat Covid-19. In this talk, Dr. Atherly will discuss the Incremental Cost Effectiveness Ratio (ICER) for three major Covid-19 policies: NMIs, vaccine development and deployment (Vaccines), and therapeutics and care improvements within the hospital setting (HTCI).
Adam Atherly, PhD, is an experienced health services research and health economist whose research spans numerous methodological and topical areas, including choice modeling, healthcare spending and expenditure modeling, evaluation of efforts to improve quality of patient care and safety, cost-effectiveness analysis (topics such as cancer and Covid-19), among others. His research often focuses on consumer decisions regarding health insurance plan choice, and, more recently, value-based healthcare. Dr. Atherly has published more than 100 peer review papers and book chapters, many with a focus on the effect of health on health care spending. Dr. Atherly is also an experienced teacher and has taught courses ranging from introductory undergraduate courses to doctoral seminars.